Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804161 | 0.76 | SIGMAR1 (0.30) | SIGMAR1 | |
| SCHEMBL7851386 | 0.72 | — | — | |
| SCHEMBL2078295 | 0.72 | — | — | |
| SCHEMBL9835272 | 0.70 | DRD3 (0.32) | DRD3 | |
| SCHEMBL7598071 | 0.69 | — | — | |
| SCHEMBL16901706 | 0.69 | — | — | |
| SCHEMBL7703025 | 0.69 | HTR3A (0.30) | — | |
| SCHEMBL2297832 | 0.68 | — | — | |
| SCHEMBL21309262 | 0.68 | GBA1 (0.38) | DRD3DRD1KDM4EMTORCYP2D6 | |
| SCHEMBL300105 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533979-B2 | Amino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-03 | — | — | US | claimed |
| US-20150065478-A1 | Amino-Derivatives As Novel Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-05 | — | — | US | claimed |
| US-8916554-B2 | Amino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-12-23 | — | — | US | claimed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | claimed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | claimed |
| US-20130303506-A1 | AMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-11-14 | — | — | US | claimed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | claimed |
| US-8524711-B2 | Amino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-03 | — | — | US | claimed |
| US-8513237-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-20 | — | — | US | claimed |
| US-8501737-B2 | Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-06 | — | — | US | claimed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | claimed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | claimed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | claimed |
| US-20050222414-A1 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | US | claimed |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | claimed |
| US-20050165016-A1 | used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability | JANSSEN PHARMACEUTICA NV (BE) | 2005-07-28 | — | — | US | claimed |
| US-20050148613-A1 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | claimed |
| US-20050119250-A1 | Antiproliferative agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | claimed |
| US-20050107384-A1 | to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2005-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107384-A1 | to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC | HDAC1, HDAC11, HDAC5 | DRD3 2799/4885DRD1 3458/4885KDM4E 208/4885 |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | DRD3 1983/4885DRD1 2611/4885KDM4E 68/4885 |
| US-20050222414-A1 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | RELA, NFE2, HDAC1 | DRD3 3033/4885DRD1 3189/4885KDM4E 89/4885 |
| US-20130303506-A1 | AMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, DOT1L | DRD3 2878/4885DRD1 3367/4885KDM4E 65/4885 |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | HDAC1, HDAC11, HDAC4 | DRD3 3395/4885DRD1 3822/4885KDM4E 112/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | DRD3 2335/4885DRD1 3094/4885KDM4E 58/4885 |
| US-20150065478-A1 | Amino-Derivatives As Novel Inhibitors Of Histone Deacetylase | HDAC1, HDAC11, DOT1L | DRD3 2878/4885DRD1 3367/4885KDM4E 65/4885 |
| US-20050119250-A1 | Antiproliferative agents | HDAC1, HDAC11, MKI67 | DRD3 4180/4885DRD1 4267/4885KDM4E 250/4885 |
| US-20050148613-A1 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | DRD3 2320/4885DRD1 2912/4885KDM4E 66/4885 |
| US-20050165016-A1 | used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability | HDAC1, HDAC11, HDAC9 | DRD3 3990/4885DRD1 3808/4885KDM4E 127/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | DRD3 2335/4885DRD1 3094/4885KDM4E 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.